glp-1 eating disorders Receptor Agonists and Research to Treat Overeating and Substance Use Neurobiological Mechanisms and Therapeutic Potential

Abstract Background The ability of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to decrease certain microvascular events has called for the investigation of GLP-1 RAs against diabetic retinopathy (DR), but the evidence is limited

These practices guarantee that each consignment meets expectations and regulatory requirements alike

Choline and risk of neural tube defects in a folate-fortified population

Recalls & Warnings November 21, 2013 FDA Warns of Five More Weight Loss Supplements Containing Undeclared Drugs On November 21, 2013, the FDA warned consumers not to buy or use the following weight loss supplements because they were found to contain one or both of the undeclared drugs sibutramine and phenolphthalein: Recalls & Warnings December 12, 2014 Marketers of HCG Settle FTC Charges of Deceptive Weight Loss Claims Marketers of HCG Platinum drops have agreed to pay $1 million to settle Federal Trade Commission (FTC) charges that claims the drops could cause rapid and substantial weight loss were deceptive and not supported by scientific evidence